Clinical trial
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00030537 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030537 |
|---|---|
| Title | Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer |
| Official title | A Pilot Study to Evaluate Epidermal Growth Factor Receptor Signaling After Treatment With Oral OSI-774 in Patients With Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Start date | Nov 1, 2001 |
| Completion | Mar 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: